

## DAFTAR PUSTAKA

- Arteaga, C. L., & Engelman, J. A. (2014). ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. *Cancer cell*, 25(3), 282-303. <https://doi.org/10.1016/j.ccr.2014.02.025>
- Bif, M. B., Yunes, J. S., & Resgalla Jr, C. (2013). Evaluation of mysids and sea urchins exposed to saxitoxins. *Environmental Toxicology and Pharmacology*, 36(3), 819-825. <https://doi.org/10.1016/j.etap.2013.06.015>.
- Bio-Rad Laboratories. (2006). *Real-Time PCR Applications Guide* (Bulletin 4106228). Bio-Rad Laboratories. Diakses dari: <https://www.bio-rad.com/sites/default/files/webroot/web/pdf/lsr/literature/4106228.pdf>
- Burdall, S. E., Hanby, A. M., Lansdown, M. R., & Speirs, V. (2003). Breast cancer cell lines: friend or foe?. *Breast cancer research*, 5, 1-7. <https://doi.org/10.1186/bcr577>.
- Burguin, A., Diorio, C., & Durocher, F. (2021). Breast cancer treatments: updates and new challenges. *Journal of personalized medicine*, 11(8), 808. <https://doi.org/10.3390/jpm11080808>.
- Carpenter, L. C., Pérez-Verdugo, F., & Banerjee, S. (2023). Mechanical control of cell proliferation patterns in growing tissues. *bioRxiv : the preprint server for biology*, 2023.07.25.550581. <https://doi.org/10.1101/2023.07.25.550581>.
- Cirino, P., Brunet, C., Ciaravolo, M., Galasso, C., Musco, L., Vega Fernández, T., *et al.* (2017). The sea urchin *Arbacia lixula*: A novel natural source of astaxanthin. *Marine drugs*, 15(6), 187. <https://doi.org/10.3390/md15060187>
- Damiani, E., Solorio, J. A., Doyle, A. P., & Wallace, H. M. (2019). How reliable are in vitro IC50 values? Values vary with cytotoxicity assays in human glioblastoma cells. *Toxicology Letters*, 302, 28-34. <https://doi.org/10.1016/j.toxlet.2018.12.004>
- Deepak, K. G. K., Kumari, S., Shailender, G., & Malla, R. R. (2020). Marine natural compound cyclo (L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling. *Chemico-biological interactions*, 315, 108872. <https://doi.org/10.1016/j.cbi.2019.108872>
- Dewi, G. A. T., & Hendrati, L. Y. (2015). Analisis risiko kanker payudara berdasar riwayat pemakaian kontrasepsi hormonal dan usia menarche. *Jurnal Berkala Epidemiologi*, 3(1), 12-23. <https://e-journal.unair.ac.id/JBE/article/download/1309/1068>.
- Duronio, R. J., & Xiong, Y. (2013). Signaling pathways that control cell proliferation. *Cold Spring Harbor perspectives in biology*, 5(3), a008904. doi: 10.1101/cshperspect.a008904
- Eitsuka, T., Tatewaki, N., Nishida, H., Nakagawa, K., & Miyazawa, T. (2016). Synergistic anticancer effect of tocotrienol combined with chemotherapeutic agents or dietary components: a review. *International Journal of Molecular Sciences*, 17(10), 1605. <https://doi.org/10.3390/ijms17101605>.

- Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., *et al.* (2022). Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. *Frontiers in Oncology*, 12, 891652. <https://doi.org/10.3389/fonc.2022.891652>.
- Geneaid Biotech Ltd. *GENEzol™ Reagent*. Diakses dari <https://geneaid.com/data/files/1606201218655841537.pdf>
- Guo, Y. J., Pan, W. W., Liu, S. B., Shen, Z. F., Xu, Y., & Hu, L. L. (2020). ERK/MAPK signalling pathway and tumorigenesis. *Experimental and therapeutic medicine*, 19(3), 1997-2007.
- Harrison, D. A. (2012). The jak/stat pathway. *Cold Spring Harbor perspectives in biology*, 4(3), a011205.
- Hero, S. (2021). Faktor Risiko Kanker Payudara. *Jurnal Medika Hutama*, 3(01 Oktober), 1533-1537.
- Hsu, J. L., & Hung, M.-C. (2016). The role of HER2, *EGFR*, and other receptor tyrosine kinases in breast cancer. *Cancer and Metastasis Reviews*, 35(4), 575–588. doi:10.1007/s10555-016-9649-6
- Kabel, A. M., & Baali, F. H. (2015). Breast cancer: insights into risk factors, pathogenesis, diagnosis and management. *Journal of Cancer Research and Treatment*, 3(2), 28-33.
- Karami Fath, M., Babakhaniyan, K., Zokaei, M., Yaghoubian, A., Akbari, S., Khorsandi, M., *et al.* (2022). Anti-cancer peptide-based therapeutic strategies in solid tumors. *Cellular & Molecular Biology Letters*, 27(1), 33. <https://doi.org/10.1186/s11658-022-00332-w>
- Kashyap, A. K., & Dubey, S. K. (2022). Molecular mechanisms in cancer development. In B. Jain & S. Pandey (Eds.), *Understanding cancer* (pp. 79–90). Academic Press. <https://doi.org/10.1016/B978-0-323-99883-3.00016-0>.
- Kementerian Kelautan dan Perikanan. (2022). *Kelautan dan Perikanan dalam Angka Tahun 2022*. Indonesia: Pusat Data, Statistik dan Informasi. hh. 121.
- Kumar, V., Abbas, A. K., & Aster, J. C. (2017). *Robbins Basic Pathology: Robbins Basic Pathology E-Book*. Elsevier Health Sciences. hh. 24-742.
- Liberti, M. V., & Locasale, J. W. (2016). The Warburg Effect: How Does it Benefit Cancer Cells?. *Trends in biochemical sciences*, 41(3), 211–218. <https://doi.org/10.1016/j.tibs.2015.12.001>
- Luparello, C., Branni, R., Abruscato, G., Lazzara, V., Sugár, S., Arizza, V., *et al.* (2022). Biological and proteomic characterization of the anti-cancer potency of aqueous extracts from cell-free coelomic fluid of *Arbacia lixula* sea urchin in an in vitro model of human hepatocellular carcinoma. *Journal of Marine Science and Engineering*, 10(9), 1292. <https://doi.org/10.3390/jmse10091292>
- Luparello, C., Ragona, D., Asaro, D. M. L., Lazzara, V., Affranchi, F., Arizza, V., *et al.* (2020). Cell-free coelomic fluid extracts of the sea urchin *Arbacia lixula* impair mitochondrial potential and cell cycle distribution and stimulate reactive oxygen species production and autophagic activity in triple-negative MDA-MB231 breast cancer cells. *Journal of Marine Science and Engineering*, 8(4), 261. <https://doi.org/10.3390/jmse8040261>

- Mangurana, W. O. I., Yusnaini, Y., & Sahidin, S. (2019). Analisis LC-MS/MS (Liquid Chromatograph Mass Spectrometry) dan metabolit sekunder serta potensi antibakteri ekstrak n-heksana spons *Callyspongia aerizusa* yang diambil pada kondisi tutupan terumbu karang yang berbeda di perairan teluk staining. *Jurnal biologi tropis*, 19(2), 131-141.
- Matthews, H. K., Bertoli, C., & de Bruin, R. A. (2022). Cell cycle control in cancer. *Nature reviews Molecular cell biology*, 23(1), 74-88. <https://doi.org/10.1038/s41580-021-00404-3>
- McCall, B., McPartland, C. K., Moore, R., Frank-Kamenetskii, A., & Booth, B. W. (2018). Effects of astaxanthin on the proliferation and migration of breast cancer cells in vitro. *Antioxidants*, 7(10), 135. <https://doi.org/10.3390/antiox7100135>
- McMaster University (2019). *How breast cancer is treated with radiation*. McMaster University. <https://healthsci.mcmaster.ca/the-radiation-oncology-series-how-is-breast-cancer-is-treated-with-radiation/>
- Najm, A. A. K., Azfaralariff, A., Dyari, H. R. E., Othman, B. A., Shahid, M., Khalili, et al. (2021). Anti-breast cancer synthetic peptides derived from the *Anabas testudineus* skin mucus fractions. *Scientific Reports*, 11(1), 23182. <https://doi.org/10.1038/s41598-021-02007-6>
- Nhàn, N. T. T., Yamada, T., & Yamada, K. H. (2023). Peptide-based agents for cancer treatment: current applications and future directions. *International Journal of Molecular Sciences*, 24(16), 12931. <https://doi.org/10.3390/ijms241612931>
- Nicolis, O., De Los Angeles, D., & Taramasco, C. (2024). A contemporary review of breast cancer risk factors and the role of artificial intelligence. *Frontiers in Oncology*, 14, 1356014. <https://doi.org/10.3389/fonc.2024.1356014>
- Ogbuigwe, P., Pita, A. B., Knox, M. A., Velathanthiri, N., & Hayman, D. T. S. (2020). High-Yield Purification of *Giardia intestinalis* Cysts from Fecal Samples. *Current Protocols in Microbiology*, 59(1). doi:10.1002/cpmc.117
- Palomares, M.L.D., & Pauly, D. (2024). *Arbacia lixula*. SeaLifeBase. <https://www.sealifebase.ca/summary/Arbacia-lixula.html>.
- Permatasanti, A., & Hidayat, W. (2023). Potential of Indonesian Herbal as an Anti-Cancer Therapy: A Systemic Review of in vitro Studies. *Cancer management and research*, 15, 837–850. <https://doi.org/10.2147/CMAR.S414457>.
- Rasti, M., Honardar, Z., Nikseresht, M., & Owji, A. (2014). Quantitative Analysis of ErbB1 and ErbB2 Genes Amplification by a High Performance Liquid Chromatography. *Avicenna journal of medical biotechnology*, 6(4), 228–237.
- Rybak, J. A., Sahoo, A. R., Kim, S., Pyron, R. J., Pitts, S. B., Guleryuz, S., et al. (2023). Allosteric inhibition of the epidermal growth factor receptor through disruption of transmembrane interactions. *Journal of Biological Chemistry*, 299(8), 104914. <https://doi.org/10.1016/j.jbc.2023.104914>.

- Schnitt, S. J. (2010). Will Molecular Classification Replace Traditional Breast Pathology?. *International Journal of Surgical Pathology*, 18(3\_suppl), 162–166. <https://doi.org/10.1177/1066896910370771>
- Sciani, J. M., Emerenciano, A. K., Silva, J. R. M. C. D., & Pimenta, D. C. (2016). Initial peptidomic profiling of Brazilian sea urchins: *Arbacia lixula*, *Lytechinus variegatus* and *Echinometra lucunter*. *Journal of Venomous Animals and Toxins including Tropical Diseases*, 22(0), 17. <https://doi.org/10.1186/s40409-016-0071-x>
- Uribe, M. L., Marrocco, I., & Yarden, Y. (2021). *EGFR* in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. *Cancers*, 13(11), 2748. <https://doi.org/10.3390/cancers13112748>
- Vadevoo *et al.* (2023). Peptides as multifunctional players in cancer therapy. *Experimental & Molecular Medicine*, 55(6), 1099-1109. <https://doi.org/10.1038/s12276-023-01016-x>
- van den Boogaard, W. M., Komninos, D. S., & Vermeij, W. P. (2022). Chemotherapy side-effects: not all DNA damage is equal. *Cancers*, 14(3), 627. <https://doi.org/10.3390/cancers14030627>.
- Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., *et al.* (2022). Therapeutic peptides: Current applications and future directions. *Signal Transduction and Targeted Therapy*, 7, 48. <https://doi.org/10.1038/s41392-022-00904-4>
- Wargasetia T. L., Ratnawati H., Widodo N., Widyananda M.H. Bioinformatics study of sea cucumber peptides as antibreast cancer agents through *EGFR*, *PI3K*, *AKT1* and *CDK4* inhibition. *Cancer Inform.* 2021;20:11769351211031864. doi:10.1177/11769351211031864
- Widyananda, M. H., Pratama, S. K., Samoedra, R. S., Sari, F. N., Kharisma, V. D., Ansori, A. N. M., *et al.* (2021). Molecular docking study of sea urchin (*Arbacia lixula*) peptides as multi-target inhibitor for non-small cell lung cancer (NSCLC) associated proteins. *J Pharm Pharmacogn Res*, 9(4), 484-496.
- World Health organization. (2022). Breast cancer. Global Cancer Observatory. <https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf>
- World Health Organization. (2022). Indonesia. Global Cancer Observatory. <https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf>
- WoRMS Editorial Board. *Arbacia lixula* (Linnaeus, 1758). Diakses pada 26 Mei 2024. <https://www.marinespecies.org/aphia.php?p=taxdetails&id=124249>.
- Wu, D., Gao, Y., Qi, Y., Chen, L., Ma, Y., & Li, Y. (2014). Peptide-based cancer therapy: Opportunity and challenge. *Cancer Letters*, 351(1), 13–22. <https://doi.org/10.1016/j.canlet.2014.05.002>.
- Xiao, Y. F., Jie, M. M., Li, B. S., Hu, C. J., Xie, R., Tang, B., *et al.* (2015). Peptide-based treatment: a promising cancer therapy. *Journal of immunology research*, 2015. <https://doi.org/10.1155/2015/761820>.
- Yenny, S. W., Jamsari, J., Hazmi, A. A., Cuandra, K. N., Hanifah, W., Yahono, A. S., ... & Tristan, C. D. (2024). In silico analysis of *Arbacia lixula*-derived

- peptides and plasmid construction for recombinant anti-aging therapies. *Narra J*, 4(3), e1283. doi: 10.52225/narra.v4i3.1283
- Yu, S., Kim, T., Yoo, K. H., & Kang, K. (2017). The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer. *Biochemical and Biophysical Research Communications*, 486(3), 752–758. <https://doi.org/10.1016/j.bbrc.2017.03.114>.
- Zhang, H. P., Jiang, R. Y., Zhu, J. Y., Sun, K. N., Huang, Y., Zhou, H. H., *et al.* (2024). PI3K/AKT/mTOR signaling pathway: An important driver and therapeutic target in triple-negative breast cancer. *Breast Cancer*, 1-13.

